Skip to Content

Video

Rare neurological condition is ‘important potential risk’ of Pfizer’s RSV vaccine, FDA says

By Janelle Chavez, CNN Two people who received Pfizer’s respiratory syncytial virus (RSV) vaccine during a clinical trial were later diagnosed with Guillain-Barre syndrome, and the US Food and Drug Administration has asked Pfizer to conduct a safety study if the shot is approved, according to agency documents released Friday. The cases were confirmed in

Continue Reading